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ABSTRACT Escherichia coli sequence type 131 (ST131) predominates globally among
multidrug-resistant (MDR) E. coli strains. We used whole-genome sequencing (WGS)
to investigate 63 MDR E. coli isolates from 7 North Carolina community hospitals
(2010 to 2015). Of these, 39 (62%) represented ST131, including 37 (95%) from the
ST131-H30R subclone: 10 (27%) from its H30R1 subset and 27 (69%) from its H30Rx
subset. ST131 core genomes differed by a median of 15 (range, 0 to 490) single-
nucleotide variants (SNVs) overall versus only 7 within H30R1 (range, 3 to 12 SNVs)
and 11 within H30Rx (range, 0 to 21). The four isolates with identical core genomes
were all H30Rx. Epidemiological and clinical characteristics did not vary significantly
by strain type, but many patients with MDR E. coli or H30Rx infection were critically
ill and had poor outcomes. H30Rx isolates characteristically exhibited fluoroquin-
olone resistance and CTX-M-15 production, had a high prevalence of trimethoprim-
sulfamethoxazole resistance (89%), sul1 (89%), and dfrA17 (85%), and were enriched
for specific virulence traits, and all qualified as extraintestinal pathogenic E. coli. The
high overall prevalence of CTX-M-15 appeared to be possibly attributable to its asso-
ciation with the ST131-H30Rx subclone and IncF[F2:A1:B] plasmids. Some phyloge-
netically clustered non-ST131 MDR E. coli isolates also had distinctive serotypes/fimH
types, fluoroquinolone mutations, CTX-M variants, and IncF types. Thus, WGS analysis
of our community hospital source MDR E. coli isolates suggested ongoing circulation
and differentiation of E. coli ST131 subclones, with clonal segregation of CTX-M vari-
ants, other resistance genes, Inc-type plasmids, and virulence genes.
KEYWORDS extended-spectrum -lactamase (ESBL), CTX-M, multidrug-resistant
(MDR) Escherichia coli, whole-genome sequencing, community hospitals
Multidrug-resistant (MDR) Escherichia coli, including strains that produce extended-spectrum -lactamases (ESBLs), are a growing clinical and public health chal-
lenge. Since 2000, CTX-M enzymes have become the most prevalent ESBL type in
Gram-negative species, particularly among E. coli and other Enterobacteriaceae (1).
Currently, E. coli sequence type (ST) 131 (ST131), associated with CTX-M-15-type
ESBLs, predominates among MDR E. coli strains in the United States and worldwide
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(1–3). Its H30 subclone underlies the ST131 expansion (2). We showed previously that
CTX-M-producing E. coli ST131 was prevalent among ESBL-producing isolates from
community hospitals (4). Few other reports address ESBL-producing E. coli from U.S.
community settings (5, 6).
Whole-genome sequencing (WGS), an emerging tool for advanced molecular epidemi-
ological investigations involving MDR organisms, allows identification of extended resis-
tance and virulence genotypes and elucidation of transmission routes (7–13). Recently,
WGS-based phylogenetic analyses of E. coli ST131 strains identified a CTX-M-15-associated
sublineage, designated H30Rx, within ST131-H30R, which is the fluoroquinolone-
resistant subset within ST131-H30 (11). Such findings suggest that H30Rx contributes
importantly to extensive antimicrobial resistance.
Here, we used WGS to investigate the clinical and molecular epidemiology of recent
MDR E. coli isolates, especially CTX-M-producing E. coli ST131, from patients with
clinically significant infections in North Carolina community hospitals. We also analyzed
resistance genes, virulence genes, and plasmid types in relation to phylogeny.
(This work was presented in part at IDWeek2016, New Orleans, LA [poster presen-
tation no. 200].)
RESULTS
WGS of the 63 E. coli study isolates generated an average of 3,560,352 read pairs per
isolate. Metagenomic sequence classification confirmed all the isolates as E. coli. After
reference-guided assembly, all samples had 10 coverage over 75% of the ge-
nome, and 62/63 (98%) had 25 coverage over 75% of the genome (see Fig. S1 in
the supplemental material). Therefore, nearly all the genome assemblies were suitable
for single-nucleotide variant (SNV) calling.
ST distribution. According to in silico multilocus sequence typing (MLST), ST131
was the most prevalent ST, accounting for 39 (62%) of the 63 study isolates. Among the
remaining 24 isolates (38%), the most prevalent ST was ST405 (6; 25% of the non-ST131
isolates; 10% overall). The fimH30 allele was present in 36 (92%) of the 39 ST131 isolates
versus only 2 (8%) of the 24 non-ST131 isolates (P  0.001). By phylogroup, whereas all
the ST131 isolates were from group B2 (by definition), the non-ST131 isolates were
from, in descending frequency, groups D (n  10: 2 ST38, 2 ST69, and 6 ST405), A (n 
5: 1 ST44, 1 ST167, 2 ST1284, and 1 ST1294), F (n  3: 3 ST648), B2 (n  3: 2 ST12 and
1 ST1193), B1 (n  2: 2 ST224), and undefined (n  1: 1 ST3057). By serotype, the 39
ST131 isolates were either O25:H4 (n  38 [97%]: 36 fimH30 and 2 fimH35) or O16:H5
(n  1 [3%]: fimH41), whereas the non-ST131 isolates exhibited other serotypes,
including the 6 ST405 isolates (all O102:H6).
SNV-based phylogeny. In the core genome phylogeny, the H30R1 and H30Rx
clades were placed within a larger H30R clade (Fig. 1), and other STs (i.e., ST12, ST38,
ST69, ST224, ST405, ST648, and ST1284) demonstrated similar sub-ST differentiation
(Fig. 2). Of the 39 ST131 isolates, 37 (95%) were H30R; 10 (27%) of these were H30R1 and
27 (73%) were H30Rx, including 2 (MDREc63 and MDREc70) that were classified as
H30Rx despite having fimH35, since both were placed with the other H30Rx isolates
in the WGS phylogeny. In pairwise comparisons, the median number of SNV
differences between different core genomes was 15 within ST131 overall (range, 0
to 490), including only 7 within H30R1 (range, 3 to 12 SNVs) and 11 within H30Rx
(range, 0 to 21), compared with 6,627 (range, 12 to 15,128) for the non-ST131 genomes
overall and 24 (range, 13 to 36) for the ST405 genomes.
The four instances in which different isolates exhibited identical core genomes (i.e.,
no SNVs) involved H30Rx isolates: (i) MDREc07 and MDREc42 (hospitals D, 2013, and B,
2010); (ii) MDREc13, MDREc26, and MDR62 (hospital A, 2013, 2014, and 2011); (iii)
MDREc32, MDREc36, and MDREc38 (hospital A and hospital C, all 2010); and (iv)
MDREc34 and MDREc59 (hospital A, 2010 and 2011). Some of these indistinguishable
isolates shared the same hospital location at almost the same time (MDREc36 and
MDREc38), suggesting either nosocomial transmission or multiple introductions of the
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same clone from our community, or at different times (MDREc13, MDREc26, and
MDREc62; MDREc34 and MDREc59), suggesting local endemicity for specific clones.
Patient characteristics. Of the 63 source patients for the study isolates (Table 1), 37
(59%) were admitted from home and 29 (46%) had a urinary tract infection. Community
FIG 1 Maximum-likelihood phylogram with metadata for 39 multidrug-resistant E. coli ST131 strains. The tree with the highest log likelihood (14,477.1472) is shown.
The tree is drawn to scale, with branch lengths measured in numbers of substitutions per site. The analysis involved 39 nucleotide sequences. All positions containing
gaps and missing data were eliminated. The final data set contained 4,015 total positions. Yellow shading, H30Rx isolates; green shading, H30R1 isolates.
FIG 2 Maximum-likelihood phylogram with metadata for 24 multidrug-resistant E. coli non-ST131 strains. The tree with the highest log likelihood
(120,371.7695) is shown. The tree is drawn to scale, with branch lengths measured in numbers of substitutions per site. The analysis involved 24 nucleotide
sequences. All positions containing gaps and missing data were eliminated. The final data set contained 17,336 total positions.
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onset health care-associated infections were the most common (30 [48%]), followed by
community-acquired infections (22 [35%]); hospital-acquired infections were uncom-
mon (6 [10%]). Forty-nine (78%) patients survived, while 5 (8%) died during hospital-
ization. Clinical and epidemiological characteristics did not vary significantly in relation
to strain type, except for an association of non-H30Rx ST131 isolates with hospital D.
TABLE 1 Clinical and epidemiological characteristics of 63 community hospital patients with multidrug-resistant E. coli infections
Categorya Specific variableb
No. of isolates (column %)
Total
(n  63)
ST131
(n  39)
Non-ST131
(n  24)
ST131
H30Rx
(n  27)
ST131
non-H30Rx
(n  12)
All non-H30Rx
(n  36)
Age 65 38 (60) 24 (62) 14 (58) 16 (59) 8 (67) 22 (61)
Sex Male 30 (48) 19 (49) 11 (46) 14 (52) 5 (42) 16 (44)
Female 26 (41) 18 (46) 8 (33) 11 (41) 7 (58) 15 (42)
Unknown 7 (11) 2 (5) 5 (21) 2 (7) 0 5 (14)
Race African American 19 (30) 12 (31) 7 (29) 8 (30) 4 (33) 11 (31)
American Indian 1 (2) 0 1 (4) 0 0 1 (3)
Asian 1 (2) 0 1 (4) 0 0 1 (3)
Caucasian 33 (52) 23 (59) 10 (42) 15 (56) 8 (67) 18 (50)
Hispanic 1 (2) 1 (3) 0 1 (4) 0 0
Unknown 8 (13) 3 (8) 5 (21) 3 (11) 0 5 (14)
Community hospital A 35 (56) 21 (54) 14 (58) 16 (59) 5 (42) 19 (53)
B 6 (10) 4 (10) 2 (8) 3 (11) 1 (8) 3 (8)
C 10 (16) 6 (15) 4 (17) 6 (22) 0 4 (11)
D 8 (13) 7 (18) 1 (4) 1 (4) 6 (50) 7 (19)
E 1 (2) 1 (3) 0 1 (4) 0 0
F 1 (2) 0 1 (4) 0 0 1 (3)
G 2 (3) 0 2 (8) 0 0 2 (6)
Admission source Home 37 (59) 21 (54) 16 (67) 12 (44) 9 (75) 25 (69)
Nursing home 13 (21) 10 (26) 3 (13) 8 (30) 2 (17) 5 (14)
Transfer from hospital 4 (6) 3 (8) 1 (4) 2 (7) 1 (8) 2 (6)
Other extended-care facility 3 (5) 3 (8) 1 (4) 3 (11) 0 1 (3)
Unknown 5 (8) 2 (5) 3 (13) 2 (7) 0 3 (8)
Type of infection Urinary tract infection 29 (46) 19 (49) 10 (42) 13 (48) 6 (50) 16 (44)
Bloodstream infection 21 (33) 14 (36) 7 (29) 9 (33) 5 (42) 12 (33)
Pneumonia 1 (2) 0 1 (4) 0 0 1 (3)
Other 7 (11) 4 (10) 3 (13) 3 (11) 1 (8) 4 (11)
Unknown 5 (8) 2 (5) 3 (13) 2 (7) 0 3 (8)
Acquisition Community acquired 22 (35) 14 (36) 8 (33) 8 (30) 6 (50) 14 (39)
Community onset, health care associated 30 (48) 20 (51) 10 (42) 15 (56) 5 (42) 15 (42)
Hospital onset, health care associated 6 (10) 3 (8) 3 (13) 2 (7) 1 (8) 4 (11)
Unknown 5 (8) 2 (5) 3 (13) 2 (7) 0 3 (8)
ICU stay Before infection 4 (6) 2 (5) 2 (8) 1 (4) 1 (8) 3 (8)
After infection 46 (73) 30 (77) 16 (67) 20 (74) 10 (83) 26 (72)
Unknown 13 (21) 7 (18) 6 (25) 6 (22) 1 (8) 7 (19)
Dialysis Yes 4 (6) 3 (8) 1 (4) 3 (11) 0 1 (3)
No 51 (81) 32 (82) 19 (79) 20 (74) 12 (100) 31 (86)
Unknown 8 (13) 4 (10) 4 (17) 4 (15) 0 4 (11)
Outcome Died 5 (8) 4 (10) 1 (4) 3 (11) 1 (8) 2 (6)
Survived 49 (78) 30 (77) 19 (79) 20 (74) 10 (83) 29 (81)
Discharged home 22 (35) 15 (38) 7 (29) 9 (33) 6 (50) 13 (36)
Discharged to hospice 5 (8) 2 (5) 3 (13) 2 (7) 0 3 (8)
Discharged to LTCF 16 (25) 11 (28) 5 (21) 8 (30) 3 (25) 8 (22)
Discharged to other facility 6 (10) 2 (5) 4 (17) 1 (4) 1 (8) 5 (14)
Unknown 9 (14) 5 (13) 4 (17) 4 (15) 1 (8) 5 (14)
aCategory of clinical or epidemiological characteristic.
bLTCF, long-term-care facility. All comparisons (ST131 versus non-ST131, H30Rx versus non-H30Rx ST131, or H30Rx versus non-H30Rx) yielded P values of 0.05,
except for community hospital category D (for H30Rx versus non-H30Rx ST131, P  0.002).
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Resistance phenotypes and genotypes. Although most or all isolates were sus-
ceptible to imipenem, ertapenem, amikacin, and minocycline, most (80 to 90%) were
resistant to trimethoprim-sulfamethoxazole and fluoroquinolones (ciprofloxacin and
levofloxacin) (Table 2 and Fig. 3), drugs that are commonly used orally to treat urinary
tract infections in community hospitals (4). Compared to non-H30Rx ST131 isolates, or
all non-H30Rx isolates, H30Rx isolates had higher resistance prevalences for most
antibiotics (Table 2). Accordingly, they had significantly higher aggregate resistance
scores (median score [interquartile range], 6 [5 to 6] for H30Rx versus 3.5 [3 to 4] for
non-H30Rx ST131 isolates [P  0.001] and 4 [3 to 6] for all non-H30Rx isolates [P 
0.02]).
WGS analysis identified multiple resistance genes and plasmids, plus associations of
blaCTX-M with diverse classes of antimicrobial resistance (Fig. 3; see Table S1 in the
supplemental material). Whereas CTX-M-15 was closely associated with H30Rx isolates
(P  0.001), CTX-M-14 was associated with non-H30Rx ST131 isolates, both overall (P 
0.002) and within ST131 (P  0.006) (Table 2). All 37 H30R isolates contained charac-
teristic H30-associated quinolone resistance-determining region (QRDR) mutations,
including gyrA 1A1B1 (S83L/D87N), parC 1a1A1B1 (S80I/E84V), and parE 3L (I529L) (P 
0.001 for H30Rx versus all non-H30Rx isolates and for ST131 versus non-ST131).
Additionally, 15 (56%) of the 27 H30Rx isolates, but only 1 (8%) of the 12 non-H30Rx
ST131 isolates, possessed the plasmid-mediated quinolone resistance determinant
aac(6=)-Ib-cr (P 0.01). H30Rx isolates also had a significantly higher frequency than did
all non-H30Rx isolates of certain non-quinolone resistance genes (i.e., aadA1, aadA5,
catB3, and dfrA17).
Virulence genes. ST131 (versus non-ST131) and H30Rx (versus non-H30Rx) isolates
were significantly enriched with specific virulence genes (i.e., pap, sfa, yfcV, iss, kps, iha,
iuc, iutA, sat, and malX) (Table 3; see Table S2 in the supplemental material). Accord-
ingly, they had significantly higher aggregate virulence scores (median score [inter-
quartile range], 22 [21 to 23] for ST131 versus 14 [12.25 to 17.5] for non-ST131, P 
0.001, and 22 [21 to 23] for H30Rx versus 15.5 [13 to 21] for all non-H30Rx, P  0.001).
Likewise, a much greater proportion qualified as extraintestinal pathogenic E. coli
(ExPEC), i.e., 37 (95%) of 39 ST131 isolates, including all 27 H30Rx isolates, versus 8
(33%) of 24 non-ST131 isolates (P  0.001 for all comparisons). However, despite their
differences in virulence gene content, these strain groups did not differ significantly in
associated clinical outcomes (Table 1). Regardless of the strain type, 46 (73%) of 63
patients were admitted to an intensive care unit (ICU) after infection, and 10 (16%) died
or were discharged to hospice.
Plasmid replicon families/types. H30Rx isolates contained IncFIA plasmid types
more frequently, and IncFIB plasmid types less frequently, than other isolates (P 
0.001) (Table 4). In silico pMLST associated IncF[F2:A1:B] with H30Rx and IncF[F1:A2:
B20] with H30R1, whereas neither of these IncF types appeared in non-ST131 isolates.
Other results for non-ST131 isolates. The non-ST131 isolates exhibited associa-
tions analogous to those noted among the ST131 isolates between specific STs and
distinctive serotypes/fimH types (for ST12, ST38, ST69, ST224, ST405, ST648, and
ST1284), QRDR mutations (for ST12, ST224, ST405, ST648, and ST1284), CTX-M variants
(for ST1284, ST224, ST405, and ST648), and IncF types (for ST224 and ST648) (Fig. 2). All
ST405 isolates had identical QRDR mutations (gyrA 20A1B1 [S83L/D87N], parC 5A1
[S80I], and parE 1A1 [S458A]), which were distinct from those associated with ST131.
DISCUSSION
We used WGS to analyze MDR E. coli isolates collected over 6 years from community
hospitals in North Carolina to identify molecular markers of resistance, virulence, and
transmission. To our knowledge, this is the first WGS study of clinical MDR E. coli isolates
from community hospital inpatients.
We found that ST131 was by far the most prevalent lineage (62% overall) and was
represented mainly by H30Rx (69% of ST131 isolates), followed by H30R1 (26% of ST131
isolates). This dominance of H30Rx within ST131 is likely due to our focus on MDR E. coli
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and the typically more extensive resistance profiles of H30Rx isolates compared with
other ST131 isolates, including even members of the fluoroquinolone-resistance-
associated H30R1 subclone (11).
We also documented clonal segregation of CTX-M variants, other resistance genes,
and Inc-type plasmids, both within ST131 and among non-ST131 isolates. With finer
resolution than MLST, WGS-based genotyping identified a variety of SNVs among
isolates from the same ST or even sub-ST clade, demonstrating mainly dissemination of
diverse H30R1/H30Rx strains throughout the study community rather than focal nos-
ocomial or community outbreaks affecting a single community hospital. The endemic-
ity documented here suggested that H30R1/H30Rx strains were circulating prior to the
study period. Based on previous epidemiological data, the introduction of these strains
likely occurred from 2006 through 2007, when the rate of ESBL-producing E. coli
infection in our network of community hospitals rose from 0 to 12 patients per 100,000
patient-days (14).
The SNV-based phylogeny showed differentiation of our ST131 strains into the
previously described H30R1 and H30Rx clades (11–13). Corresponding to this clonal
structure, we identified the IncFIA and IncFII (e.g., IncF[F2:A1:B]) replicons in most
H30Rx isolates that produced CTX-M-15. While ST131 can harbor ESBL-encoding plas-
mids of different incompatibility groups, blaCTX-M-15 has been associated primarily with
IncF, especially FIA-FII fusion or FII replicons (3). A recent WGS study of ST131 isolates
FIG 3 Distribution of acquired resistance genes and plasmids within 63 multidrug-resistant E. coli strains. Antimicrobial susceptibility profiles (R, resistant; blank,
susceptible) and presence (black)/absence (white) of resistance genes and plasmids for each isolate are shown. SAM, ampicillin-sulbactam; TZP, piperacillin-
tazobactam; CRO, ceftriaxone; FEP, cefepime; IMP, imipenem; EPM, ertapenem; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; LVX, levofloxacin; SXT,
trimethoprim-sulfamethoxazole; MIN, minocycline. Yellow shading, H30Rx isolates; green shading, H30R1 isolates.
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from the United States likewise described associations of IncF[F2:A1:B] with H30Rx
and IncF[F1:A2:B20] with H30R1, demonstrating fixation and ongoing evolution of
specific plasmids within these separate but closely related sublineages (15). Our data
extend these findings to community hospital source ST131 isolates.
All H30R study isolates had distinctive H30R-associated double nonsynonymous
mutations in gyrA and parC (16–18), which confer high-level quinolone resistance
(13). The H30Rx strains additionally harbored aac(6=)Ib-cr (encoding a dual-function
aminoglycoside- and fluoroquinolone-modifying enzyme) significantly more frequently
than other strains, supporting an association of the gene specifically with H30Rx (18).
They also exhibited a high prevalence of trimethoprim-sulfamethoxazole resistance
(89%), sul1 (89%), and dfrA17 (85%) and had higher aggregate resistance scores than
other strains, consistent with other reports from the United States and elsewhere (9, 19,
TABLE 3 Putative virulence genes among 63 multidrug-resistant E. coli isolates from community hospitals
Category
Virulence
gene
No. (column %) of isolates P valuea
Total
(n  63)
ST131
(n  39)
Non-ST131
(n  24)
ST131
H30Rx
(n  27)
ST131
non-H30Rx
(n  12)
All non-H30Rx
(n  36)
ST131 vs
non-ST131
H30Rx vs
all
non-H30Rx
Adhesin dra 13 (21) 12 (31) 1 (4) 8 (30) 4 (33) 5 (14) 0.01
fim 59 (94) 39 (100) 20 (83) 27 (100) 12 (100) 32 (89) 0.02
nfaE 13 (21) 12 (31) 1 (4) 8 (30) 4 (33) 5 (14) 0.01
pap 44 (70) 37 (95) 7 (29) 27 (100) 10 (83) 17 (47) 0.001 0.001
sfa 44 (70) 37 (95) 7 (29) 27 (100) 10 (83) 17 (47) 0.001 0.001
yfcV 45 (71) 39 (100) 6 (25) 27 (100) 12 (100) 18 (50) 0.001 0.001
Protectin iss 48 (76) 38 (97) 10 (42) 27 (100) 11 (92) 21 (58) 0.001 0.001
kfiC 12 (19) 11 (28) 1 (4) 5 (19) 6 (50) 7 (19) 0.02
kps 47 (75) 38 (97) 9 (38) 27 (100) 11 (92) 20 (56) 0.001 0.001
Siderophore chu 55 (87) 38 (97) 17 (71) 26 (96) 12 (100) 29 (81) 0.004
fyuA 58 (92) 39 (100) 19 (79) 27 (100) 12 (100) 31 (86) 0.006
iha 39 (62) 36 (92) 3 (13) 26 (96) 10 (83) 13 (36) 0.001 0.001
irp 58 (92) 39 (100) 19 (79) 27 (100) 12 (100) 31 (86) 0.006
iuc 47 (75) 35 (90) 12 (50) 25 (93) 10 (83) 22 (61) 0.001 0.007
iutA 47 (75) 35 (90) 12 (50) 25 (93) 10 (83) 22 (61) 0.001 0.007
Toxin sat 38 (60) 35 (90) 3 (13) 25 (93) 10 (83) 13 (36) 0.001 0.001
Miscellaneous malX 53 (84) 39 (100) 14 (58) 27 (100) 12 (100) 26 (72) 0.001 0.003
ExPEC NAb 45 (71) 37 (95) 8 (33) 27 (100) 10 (83) 18 (50) 0.001 0.001
aOnly P values of 0.05 are shown.
bNA, not applicable.
TABLE 4 Plasmid replicon families and plasmid MLST (pMLST) among 63 multidrug-resistant E. coli isolates from community hospitals
Plasmid replicon
family/pMLST
No. (column %) of isolates P valuea
Total
(n  63)
ST131
(n  39)
Non-ST131
(n  24)
ST131
H30Rx
(n  27)
ST131
non-H30Rx
(n  12)
All non-H30Rx
(n  36)
ST131 vs
non-ST131
H30Rx vs
non-H30Rx
ST131
H30Rx vs all
non-H30Rx
IncB/O/K/Z 3 (5) 1 (3) 2 (8) 1 (4) 0 2 (6)
IncFIA 46 (73) 34 (87) 12 (50) 27 (100) 7 (58) 19 (53) 0.003 0.001 0.001
IncFIB 35 (56) 16 (41) 19 (79) 8 (30) 8 (67) 27 (75) 0.004 0.04 0.001
IncFIC 2 (3) 0 2 (8) 0 0 2 (6)
IncFII 55 (87) 35 (90) 20 (83) 24 (89) 11 (92) 31 (86)
IncI 9 (14) 5 (13) 4 (17) 3 (11) 2 (17) 6 (17)
IncN 5 (8) 3 (8) 2 (8) 1 (4) 2 (17) 4 (11)
IncQ 2 (3) 0 2 (8) 0 0 2 (6)
IncX 5 (8) 2 (5) 3 (13) 2 (7) 0 3 (8)
IncY 6 (10) 2 (5) 4 (17) 1 (4) 1 (8) 5 (14)
pSL483 1 (2) 1 (3) 0 0 1 (8) 1 (3)
Col 49 (78) 30 (77) 19 (79) 21 (78) 9 (75) 28 (78)
F2:A1:B 18 (29) 18 (46) 0 18 (67) 0 0 0.001 0.001 0.001
F1:A2:B20 6 (10) 6 (15) 0 1 (4) 5 (42) 5 (14) 0.007
aOnly P values of 0.05 are shown.
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20). These features may give H30Rx strains a competitive advantage over other ESBL-
producing strains, especially with use of fluoroquinolones and extended-spectrum
cephalosporins (21, 22), thereby contributing to their epidemiological success.
As observed previously (23, 24), most ST131 study isolates and all H30Rx isolates
qualified as ExPEC, with an extensive array of putative virulence genes and higher
virulence scores, suggesting high virulence potential. However, higher virulence
scores were not associated with worse clinical outcomes. Among ST131/H30Rx
strains, host characteristics may confound associations of virulence genes with
clinical severity and/or mortality (21). Nonetheless, in a recent analysis, the H30
subclone was significantly associated with persistent infections and adverse out-
comes despite multivariable adjustment for underlying host factors and resistance
to the prescribed antibiotic (21). In our study, a majority of patients with H30Rx
were critically ill and had poor outcomes (i.e., 74% frequency of ICU admission after
infection and 11% all-cause mortality), although this did not differ significantly from
other strain groups.
It remains unclear whether the most extensively resistant E. coli ST131 strains are
from the community or health care setting (2). In a recent study of unselected E. coli
clinical isolates from the U.S. Midwest, ST131 was associated with young children and
the elderly, antimicrobial resistance, and health care-associated infections (25). In
contrast, in our North Carolina community hospital-based study of MDR E. coli isolates,
we observed no significant difference in patient age or site of infection acquisition
between ST131 and non-ST131 strains or between H30Rx and non-H30Rx ST131 strains.
Our results establish that health care personnel in community hospitals may encounter
MDR E. coli ST131 in patients with community-acquired infection, community onset
health care-associated infections, or hospital onset health care-associated infections.
This indicates a need to facilitate appropriate antimicrobial therapy and infection
control measures against MDR E. coli ST131 in community hospitals.
In that regard, approximately 80% of the present community hospital MDR E. coli
infections were present on admission with or without prior health care exposure,
similar to our previous finding (4). Additionally, various movements of patients with
MDR E. coli ST131-H30Rx occurred among different health care facilities, both before
admission to and after discharge from our community hospitals (e.g., admission from
home to community hospital and then discharge to home, nursing home, or hospice)
(see Table S3 in the supplemental material). This emphasizes potential routes for strain
dissemination and the important role of community hospitals and transferring/receiv-
ing health care facilities as reservoirs of MDR E. coli.
Although previous WGS studies have investigated E. coli ST131 (11–13), to our
knowledge, none has addressed the molecular epidemiology of non-ST131 MDR E. coli.
Here, although most non-ST131 isolates, like the ST131 isolates, produced CTX-M
variants (e.g., CTX-M-15 or CTX-M-14) and exhibited quinolone resistance, they had
different QRDR mutations and IncF types than did the ST131 strains. Although ST131 is
currently the most prevalent MDR E. coli strain in our community and globally, attention
to resistance in non-ST131 E. coli also is clearly warranted.
This study has several limitations. First, limited clinical and epidemiological data
were available from our surveillance databases, although data entry and definitions
were standardized across participating hospitals. Second, our sample was derived from
multiple centers over a 6-year period, adding breadth to our analysis, but at the
expense of depth. While this reduced our power to detect meaningful associations, it
may increase the generalizability of our findings. Third, our small sample size limited
the power to confirm statistical associations, particularly for non-ST131 isolates.
In summary, our WGS analysis of MDR E. coli isolates from community hospitals in North
Carolina (2010 to 2015) provides insights into the diversity of their resistance and
virulence genes and their complex transmission dynamics in our community,
including at the level of STs, subclones, and plasmids, especially for the CTX-M-
producing ST131-H30Rx subclone. Our findings both confirm those of previous similar
studies and uniquely extend them to community hospitals (11–13). The striking dom-
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inance of H30Rx strains carrying IncF[F2:A1:B] plasmids suggests that this lineage
represents an especially successful combination of extensive resistance and virulence.
Further genomic-epidemiological studies of E. coli ST131 and its H30R1 and H30Rx
subclones are needed in community hospitals to inform antimicrobial stewardship
programs, empirical therapy approaches, and infection control strategies rooted in the
community.
MATERIALS AND METHODS
Bacterial isolates. The study sites were 7 geographically dispersed community hospitals in or near
North Carolina affiliated with the Duke Infection Control Outreach Network (DICON). Between 2010 and
2015, local infection preventionists prospectively used Centers for Disease Control and Prevention
surveillance definitions (26) to identify all hospitalized patients with MDR E. coli infections. Isolates were
classified as MDR if they were nonsusceptible to 1 agent in 3 antimicrobial classes (27). The hospital
laboratories confirmed ESBL production phenotypically by using Clinical and Laboratory Standards
Institute (CLSI) criteria. Duke University’s Institutional Review Board approved the study.
During 2010 to 2015, the study hospitals reported 100 total MDR E. coli infections. Sixty-three
nonduplicate MDR E. coli isolates (54 were ESBL producers), including 61 from 6 North Carolina hospitals
and 2 from 1 Virginia hospital, were saved in the DICON Biorepository and subsequently sent to the
University of North Carolina at Chapel Hill (UNC) for further analysis.
Clinical and epidemiological data. Clinical and epidemiological data for the source patients were
obtained through the DICON database. Variables included age, sex, race, admission source, type of
infection, setting for infection acquisition, presence/absence of ICU stay, dialysis use, and discharge
outcome.
Antimicrobial susceptibility testing. The UNC Clinical Laboratories reassessed isolates’ susceptibil-
ity to 12 antibiotics by disk diffusion according to the 2015 CLSI guideline (28). Isolates classified as
intermediate or resistant were regarded as resistant.
Whole-genome sequencing. Isolates were grown overnight in LB broth at 37°C. Total DNA was
extracted and purified using an UltraClean microbial DNA isolation kit (Mo Bio, Carlsbad, CA). Sequencing
libraries were prepared using the NEBNext Ultra DNA Library Prep kit for Illumina (New England BioLabs,
Ipswich, MA) with NEBNext Multiplex oligonucleotides (New England BioLabs). Size-fractionated DNA
libraries were labeled, pooled, and sequenced at the UNC High-Throughput Sequencing Facility in a
single Illumina HiSeq2500 run using 125-base paired-end V4 chemistry.
Sequence assembly and mapping. De novo and reference-guided assembly methods were used for
gene identification and comparative genetic analysis, respectively, unless otherwise noted. De novo
assemblies were compiled using the A5-miseq pipeline with default parameter settings (29). Reference-
guided assemblies against E. coli strain EC958 (GenBank accession no. HG941718.1) were compiled using
bwa mem (30) (see Fig. S1 in the supplemental material). Assemblies were deduplicated and subjected
to local realignment through high-entropic regions using Picard (http://broadinstitute.github.io/picard/)
and the Genome Analysis Toolkit (GATK) v3.3 (31).
Variant calling. SNVs were identified by applying the GATK UnifiedGenotyper across all reference-
aligned isolates simultaneously. The SNVs were filtered stringently using cutoffs responsive to the
underlying distribution of quality scores. For filtering, the parameters included the following: quality by
depth,  25; mapping quality, 59; Fisher score, 4; map quality rank sum, 4.0; and read position
rank sum, 4.0.
Genetic analysis. Species identification was confirmed by k-mer-based classification based on
short-read sequences using Kraken (32). Phylogenetic groups were inferred from known ST assignments
(33). Specific genes and alleles thereof were identified via the Center for Genomic Epidemiology’s
bioinformatic pipeline (http://www.genomicepidemiology.org/), using default settings except where
otherwise stated. Specifically, serotypeFinder 1.1 (34) was used for serotypes, FimTyper 1.0 (35) for fimH
types, MLST v1.7 (36) and the Achtman MLST scheme (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) (37) for
in silico MLST, ResFinder v2.1 (38) for acquired resistance genes (threshold, 98% identity; minimum
length, 60%), PlasmidFinder 1.3 for plasmid incompatibility groups (threshold, 95% identity), and pMLST
1.4 (39) for plasmid STs. The resistance score was the number of antimicrobial classes for which an isolate
was resistant to 1 representative agent (40).
For E. coli ST131 isolates, subclones H30R (ciprofloxacin resistant; fimH allele 30), H30Rx (a CTX-M-
15-associated clonal subset within H30R), and H30R1 (a sister clade to H30Rx within H30R) were classified
as described previously (11, 15). H30Rx was defined based on a specific SNV, ybbW G723A, as identified
by BLASTn (http://blast.ncbi.nlm.nih.gov/Blast.cgi) (19).
To investigate QRDRs, established alleles of gyrA, parC, and parE were identified using a gyrA, parC,
parE allele database generously provided by E. Sokurenko, University of Washington. Stepwise muta-
tional derivatives of each numbered allele in gyrA, parC, and parE were identified.
Virulence genes were identified using a previously described list of 119 such sequences (10). Gene
presence/absence was determined by BLASTn based on 80% sequence identity and 80% coverage
(10). Genes were classified functionally as adhesin, bacteriocin/microcin, invasin, motility, protectin,
siderophore, toxin, and miscellaneous (41). The virulence score was the number of unique virulence
operons detected, irrespective of the number of constituent genes (23). Isolates were defined as ExPEC
if positive for2 of (i) any pap, (ii) any sfa or foc, (iii) any afa or dra, (iv) any kps, and (v) iutA, as described
previously (42), with modification.
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For phylogenetic analysis, recombinant genomic regions were identified using Gubbins (43) and
were excluded. A maximum-likelihood (ML) tree was inferred using the Tamura-Nei model (44)
within MEGA7 (45) (use of the general time-reversible substitution model yielded a similar tree). The
ML phylogeny was constructed from genetic variation in nonrecombinant genomic regions. The
initial tree(s) for the heuristic search was obtained automatically by applying the neighbor-joining
and BioNJ algorithms to a matrix of pairwise distances estimated using the maximum composite
likelihood (MCL) approach and then selecting the topology with superior log likelihood value.
Pairwise SNV differences between core genomes were calculated using bedtools (https://bedtools
.readthedocs.io/en/latest/).
Statistical analysis. Using JMP 11 (Statistical Analysis System, Cary, NC, USA), categorical variables
were compared by the two-tailed Fisher test or the chi-square test, and continuous variables were
evaluated by the Wilcoxon test. The significance threshold was a P value of 0.05.
Accession number(s). Sequence data have been deposited in the DDBJ/EMBL/GenBank Sequence
Read Archive (SRA) under accession numbers DRX055674 to DRX055737.
SUPPLEMENTAL MATERIAL
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